S&P Futures
3,839.00+11.00(+0.29%)Dow Futures
31,425.00+54.00(+0.17%)Nasdaq Futures
12,833.75+2.00(+0.02%)
Protagonist Therapeutics, Inc. (PTGX)
23.99 0.00 (0.00%)
After hours: 4:01PM EST
Chart Events
Performance Outlook
| Previous Close | 25.31 |
| Open | 25.29 |
| Bid | 24.00 x 1100 |
| Ask | 24.08 x 1000 |
| Day's Range | 23.95 - 26.01 |
| 52 Week Range | 5.30 - 27.24 |
| Volume | 265,944 |
| Avg. Volume | 489,006 |
| Market Cap | 1.032B |
| Beta (5Y Monthly) | 1.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.06 |
| Earnings Date | Mar 08, 2021 - Mar 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.00 |
Fair Value
Related Research
- PR Newswire
Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at SVB Leerink Virtual 10th Annual Global Healthcare Conference taking place February 22 to February 26, 2021.
- PR Newswire
Protagonist Therapeutics Reports Granting of Inducement Award
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 29, 2021, it issued an inducement award to Paula O'Connor, M.D., the Company's recently hired Senior Vice President, Clinical Development, in accordance with the terms of Dr. O'Connor's employment offer letter. The award was granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020.
- Simply Wall St.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insiders Increased Their Holdings
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
